Serina Therapeutics, Inc. (SER) Stock Score, Valuation & Financial Research

Serina Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for SER

Serina Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.99. These figures are a research snapshot, not a buy or sell recommendation.

What Serina Therapeutics, Inc. does

Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Serina Therapeutics is a clinical-stage biotechnology company that develops drug candidates using its proprietary poly(2-oxazoline) (POZ) polymer technology platform. The company aims to improve the pharmacokinetic profiles of existing, well-understood drugs by attaching them to POZ polymers to reduce toxicity, minimize side effects, and extend half-life, with the goal of licensing these candidates or bringing them to market.

Products and services

The company is developing a pipeline of drug candidates based on its POZ platform, including SER-252 for the treatment of Parkinson's disease and other neurological conditions.

Customer types

Pharmaceutical and biotechnology companies (potential licensing partners).

Suppliers, materials and equipment

Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party providers for preclinical studies, clinical trials, and the manufacturing of drug candidates; specific supplier names are not disclosed. Source

Business strengths to evaluate

Proprietary POZ polymer delivery technology platform Source

Business risks and research considerations

History of operating losses and expectation of continued losses Source
Dependence on third-party clinical research and manufacturing organizations Source
Uncertainty regarding clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

SER financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:: Not currently available
Stored price:: USD 1.99
Market capitalization:: 29.85M (currency not supplied)
Revenue:: USD 0.00
Net income:: USD -21.18M
Free cash flow:: USD -18.01M
Cash:: USD 23.02M
Total debt:: USD 3.21M
EPS:: USD -1.88

What stands out

Free cash flow is USD -18.01M, negative for the stored period.
The balance sheet shows USD 23.02M of cash versus USD 3.21M of total debt, an excess of cash over debt on these two reported measures.
The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

Cash exceeds debt by USD 19.82M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for SER

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

How long can SER fund negative free cash flow using its current cash position before it may need more debt or new shares?
How is SER likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
What specifically needs to improve for SER to reach sustainable profitability?
What does the current fundamental change risk warning mean for the reliability or interpretation of SER's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research SER

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.